SCHEDULE: Millennium Management Discloses 1.3% Zentalis Stake

Millennium Management LLC and affiliates reported a 1.3% beneficial ownership stake in Zentalis Pharmaceuticals, Inc. as of September 30, 2025.

Summary

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander collectively beneficially own 902,521 shares of Zentalis Pharmaceuticals, Inc. common stock.
• This ownership represents 1.3% of Zentalis Pharmaceuticals, Inc.'s outstanding common stock.
• The reporting persons have shared voting power and shared dispositive power over all 902,521 shares.
• The filing is an Amendment No. 1 to a previous Schedule 13G statement.
• The securities were not acquired for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a factual, regulatory disclosure of beneficial ownership and does not contain information that would inherently suggest a positive or negative sentiment regarding the company's performance or prospects.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Zentalis Pharmaceuticals, Inc.'s future performance or outlook.

Industry Context

This filing reflects a routine disclosure of a passive ownership stake by a prominent hedge fund in a pharmaceutical company. It indicates continued institutional interest in Zentalis Pharmaceuticals, Inc. but does not provide insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, confirming Millennium Management's passive stake in the company.

Key Dates

Keywords

Zentalis Pharmaceuticals, Millennium Management, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor